Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-21
2011-06-21
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S340000
Reexamination Certificate
active
07964609
ABSTRACT:
The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation.
REFERENCES:
patent: 5036057 (1991-07-01), Martin
patent: 6117908 (2000-09-01), Andrews et al.
patent: 1 513 525 (2008-05-01), None
patent: WO 98/11885 (1998-03-01), None
patent: WO-9959612 (1999-11-01), None
patent: WO-0051583 (2000-09-01), None
patent: WO-0112627 (2001-02-01), None
patent: WO-0172291 (2001-10-01), None
patent: WO-02/28837 (2002-04-01), None
patent: 02/068417 (2002-09-01), None
The Merck Index, 17thedition, (1999), pp. 232-233, 237-238, 2107-2108.
Gasparini F et al: “2-METHYL-6-(phenylenthynyl)-Pyridine(MPEP), A Potent, Selective andsystemically active MGLU5 Receptor Antagonist” Neuropharmacology, Pergamon press, Oxford, GB, vol. 38 No. 10, Oct. 1999 pp. 1493-1503.
Knöpfel T el al: Metabotropic Glutamate Receptors: Novel targets for drug development Journal of Medicinal Chemisty, American Chemical Society, Washington, US, vol. 38, No. 9 Apr. 28, 1995 pp. 1417-1426.
Chen, C-Y et al., Journal of Physiology (2002), 538.3, pp. 773-786.
Pin, J-P at al., European Journal of Pharmacology (1999), 375, pp. 277-294.
Bräuner-Osborne, H et al. Journal of Medicinal Chemistry (2000), 43, pp. 2609-2645.
Schoepp, D.D, Jane D.E. Monn J.A. Neuropharmacology (1999), 38, pp. 1431-1476.
Holloway & Dent (1990) Gastroenterol. Clin. N. Amer. 19, pp. 517-535.
Martin et al., presentation at the conference Neurogastroenterology & Motility, Madison, Wisconsin, Nov. 14, 2001.
Walker et al., Neuropharmacology, vol. 40, p. 1, (1990) (Abstract).
Spooren et al., Trends Pharmacol. Sci. 22:331 (2001).
Hornby et al., “Receptors and Transmission in the Brain-Gut Axis II. Excitatory amino acid receptors in the brain-gut axis”, The Am. J. Physiological Society, 280: G1055-G1060, 2001.
Lehmann et al., “Effects of antagonism of NMDA receptors on transient lower esophageal sphincter relaxations in the dog”, European J. of Pharm. 431:253-258, 2001.
O'Leary et al., “Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism”, British J. of Pharm. 131:1429-1437, 2000.
Liu et al., “Agonist-and Reflex-Evoked Internalization of Metabotropic Glutamate Receptor 5 in Enteric Neurons”, The J. of Neuroscience, 20(9):3200-3205, May 1, 2000.
Blackshaw et al., “Gastrointestinal pharmacology.-new therapeutic vistas”, Current Opinion in Pharm. 1:561-562, 2001.
Kirchgessner, A., “Glutamate in the enteric nervous system”, Current Opinion in Pharm. 1:591-596, 2001.
J. T. Greenamyre et al., “Anatomy and physiology of glutamate in the CNS”, Neurology 44 (Suppl. 8), Nov., S7-S13, 1994.
D. P. Hirsch et al., “Involvement of Glutamate to Transient Lower Esophageal Sphincter Relaxations in Man”, Gastroenterology 120, A-630 (3197), 2001.
J. A. Saugstad et al., “L-2-amino-3-phosphonopropionic acid competitively antagonizes metabotropic glutamate receptors 1α and 5 inXenopusoocytes”, Euro. J. of Pharm. 289:395-397, 1995.
A. E. Kingston et al., “Pharmacological Analysis of 4-Carboxyphenylglycine Derivatives: Comparison of Effects on mGluR1α and mGluR5a Subtypes”, Neuropharm. vol. 34, 8:887-894, 1995.
Wise et al., “Calcium sensing properties of the GABABreceptor”,Neuropharmacology, vol. 38 (1999), pp. 1647-1656.
Bordi et al., “Group I metabotropic glutamate receptors: implications for brain diseases”,Progress in Neurobiologyvol. 59, (1999) ,pp. 55-79.
Schmidt et al., “A new phospholipase-C-calcium signaling pathway mediated by cyclic AMP and a Rap GTPase”,Nature Cell Biology, vol. 3 (2001), pp. 1020-1024; and supplementary information, p. 1.
Spooren et al., “Effects of the prototypical mGlu5receptor antagonist 2- methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats”,European Journal of Pharmacology, vol. 406 (2000), pp. 403-410.
Spooren et al., “Novel allosteric antagonists shed light on mglu5receptors and CNS disorders”,TRENDS in Pharmacological Sciences, vol. 22, No. 7 (2001), pp. 331-337.
Patentee AstraZeneca's response, dated Jun. 25, 2009, to the Opposition against EP 1 513 525 B1 filed by Addex Pharma S.A. and separately by Novartis AG.
The EPO's preliminary and non-binding opinion dated Oct. 19, 2009 with regard to the Opposition against EP 1 513 525 B1.
Supplemental submission, dated Jul. 28, 2010, by the opponent Novartis AG in its Opposition against EP 1 513 525 B1.
Trilateral Project B3b: Mutual understanding in search and examination: Report on comparative study on biotechnology patent practices: Theme—comparative study on “reach-through claims”, EPO, JPO, USPTO, Nov. 5-9, 2001.
K. Sonogashira et al., Tetrahedron Letters. (1975), 50, 4467-4470.
Lehmann Anders
Mattsson Jan
Stormann Thomas M.
Astrazeneca AB
Spivack Phyllis G.
White & Case LLP
LandOfFree
Use of mGluR5 antagonists for the treatment of gerd does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of mGluR5 antagonists for the treatment of gerd, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of mGluR5 antagonists for the treatment of gerd will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2687785